内皮素-1通过L-型钙通道的Ca^2＋内流和钙致钙释放诱导心肌细胞内[Ca^2＋]的增加

本研究利用fura-2-AM荧光成像和膜片钳技术,发现内皮素-1（Endothelin-1,ET-1）可显著提高大鼠分离心肌细胞内钙离子水平（[Ca^2＋]i）,激活心肌细胞钙通道．ETA受体阻滞剂BQ123能够消除ET-1提高[Ca^2＋]i的效应,而ETB受体阻滞剂BQ788对该效应无影响,用ryanodine受体阻断剂ryanodine（10μmol／L）预处理,可以使ET-1诱导的[Ca^2＋]i的增加抑制46.7％,蛋白激酶A（PKA）的抑制剂、蛋白激酶C（PKC）的抑制剂和血管紧张素Ⅱ-型受体（ATI receptor）的抑制剂都能够抑制ET-1诱导的[Ca^2＋]i的增加,本研究发现ET-1能够提高全细胞L-型钙通道电流的幅度,增加L-型钙通道单通道的开放概率．并且BQ123完全阻止了ET-1诱导的L-型钙通道开放概率增加的效应．本研究证明了ET-1通过一系列机制调节钙超载,包括L-型钙通道的激活,钙致钙释放（CICR）,ETA受体,PKC,PKA和血管紧张素Ⅱ-型受体也参与到了这个途径中。     

白介素—2对心肌细胞[Ca^2＋]i的作用及其信号转导途径

为研究白介素－2（interleukin-2,IL-2）对心肌细胞内钙浓度（[Ca^2 ]i）的影响及其信号转导途径,实验采用酶解法分离成年大鼠心室肌细胞,以Fura-2/AM为钙探针,用细胞内双波长钙荧光系统检测细胞[Ca^2 ]i的变化。结果发现：（1）IL－2（0.5-200U/ml）浓度依赖性地降低单个心室肌细胞内钙态,IL－2（200U／ml）对咖啡因诱导的肌浆网内储钙的释放无影响;（2）纳洛酮(naloxone,Nal)(10^-8mol/L）和nor-binaltorphimine(nor-BNI,10^-8mol/L）可阻断IL－2对心肌细胞钙瞬态的作用,而纳曲吲哚（naltrindole,NTI）（10^-6mol/L）不能阻断此作用;（3）κ阿片受体激动剂U50488H（10^-6mol/L）降低心肌细胞钙瞬态,nor-BNI(10^-8mol/L）可阻断此作用;（4）5mg/L百日咳毒素（PTX）预处理可取消IL－2降低心肌细胞钙瞬态的作用,而酪氨酸激酶抑制剂genistein(10^-4mol/L）不能取消IL－2的作用;（5）U73122预处理可阻断IL－2的作用。研究结果表明,IL－2降低心肌细胞钙瞬态的作用,是通过心肌细胞上κ阿片受体介导的,其下游途径包括PTX敏感的G蛋白和磷脂酶C。     

持续癫痫样放电导致海马神经元钙离子动力学变化的研究

目的：研究低镁介质致痫的培养海马神经元癫痫模型中神经元内游离钙离子（[Ca^2＋]i）的时空分布及其动力学改变,以探讨钙离子在癫痫发病过程中的作用。方法：联合应用共聚焦激光扫描显微镜和膜片钳,运用较高时间分辨率动态观察培养海马神经元癫痫模型[Ca^2＋]i和电生理变化,以及化学门控钙离子通道阻滞剂的影响。结果：致痫后海马神经元胞浆和核内游离钙离子迅速上升到（612±65）nmol／L和（620±69）nmol／L水平,NMDA受体阻断剂MK-801（10μmol／L）和非NMDA受体阻断剂NBQX（10μmol／L）可使[Ca^2＋]i的升高明显减少;升高的[Ca^2＋]i恢复有明显的延迟现象,90min和150min癫痫样放电后[Ca^2＋]i恢复的时间分别为（114．8±5．2）和（135．0±22．7）（P〈0．05）。结论：持续的癫痫样放电可导致海马神经元细胞内钙超载,这个效应可被MK-801阻断,化学门控钙离子通道也参与了细胞外Ca^2＋内流的过程。     

钙激活氯离子通道对大鼠肺动脉张力的调节作用

目的：研究钙激活氯离子通道及其通道阻断剂尼氟灭酸（niflumic acid,NFA）、indaryloxyacetic acid（IAA-94）在苯福林（phenylephrine,PE）引起的肺动脉收缩中的作用。方法：常规离体血管灌流法检测肺动脉环张力;采用钙荧光探针（Fura-2／AM）负载急性酶分离法（胶原酶Ⅰ型和木瓜蛋白酶）获得的大鼠肺动脉平滑肌细胞（PASMCs）,观察NFA和IAA-94对PE诱导的PASMCs胞浆游离钙离子浓度（[Ca^2＋]i）的影响,用荧光分光光度计法检测[Ca^2＋]i。结果：钙激活氯离子通道阻断剂NFA和IAA-94可以舒张PE引起的肺动脉环收缩;NFA和IAA-94对KCl引起的血管收缩无影响;PE可以引起[Ca^2＋]i升高,NFA和IAA-94对PE诱导[Ca^2＋]i升高无影响。结论：钙激活氯离子通道在生理状态下与血管活性药（PE）引起的肺动脉张力变化有关,这为研究其在低氧肺血管收缩中的作用提供了新的线索。     

整合素介导小鼠卵内钙离子增加

为了研究整合素是否作为跨膜信号传递受体介导小鼠卵[Ca^2 ]i的变化并探讨其机制。本实验采用甘-精-甘-天冬-丝-脯(GLY-ARG-GLY-ASP-SER-PRO,RGD肽)、纤连蛋A(fibronectin,Fn)及抗整合素α6、β1的单克隆抗体作用于负载了钙探针Fluo-3／AM的去透明带小鼠卵,用激光共聚焦显微镜检测小鼠卵的荧光强度以反映卵[Ca^2 ];用无钙液替代有钙液、或用酪氨酸激酶抑制剂或蛋白激酶C的抑制剂预先作用于卵,然后再观察RGD肽所致卵[Ca^2 ]i的变化。结果显示整合素配体RGD肽或Fn作用于去透明带小鼠卵可引起卵[Ca^2 ]i增加,增加的程度与精子作用相似;去除培养液中的Ca^2 后,再用RGD肽、Fn作用仍可引起卵[Ca^2 ]i增加：用功能性的抗小鼠整合素α6、β1的单克隆抗体也可引起不同程度的卵[Ca^2]i增加,尤其以抗小鼠整合素α6、β1单克隆抗体的作用明显;用酪氨酸激酶抑制剂预先作用于鼠卵,RGD肽或精子作用都不再引起卵[Ca^2 ]i增加;蛋白激酶C抑制剂预先作用鼠卵,RGD肽及Fn也不再引起卵[Ca^2 ]i增加。实验证明。小鼠卵膜整合素与其配体结合可使卵内贮存钙离子释放,引起卵[Ca^2 ]i增加这一卵激活的早期事件;整合素介导小鼠卵激活需要酪氨酸激酶信号转导途径的参与;蛋白激酶C也参与了整合素介导的卵激活。     

磷酸脂酶C—γ的信号传递研究进展

信号分子磷脂酶C－γ（PLC－γ）被蛋白酪氨酸酶（PTK）激活催化水解磷脂酰肌醇4,5－二磷酸（PIP2）生成第二信使分子肌醇三磷酸（IP3）和二酰基甘油（DAG）,参与受体酪氨酸激酶（RTK）介导的细胞分列、抗原与免疫细胞受体结合引起免疫反应及卵细胞受精等过程中的信号传递。     

青藤碱对培养VSMC MAPK、PKC活性和细胞[Ca^2＋]i的影响

目的：观察青藤碱对血管平滑肌细胞（VSMC）丝裂素活化蛋白激酶（MAPK）、蛋白激酶C（PKC）活性和胞内游离钙浓度（[Ca^2＋i]）的影响。方法：将VSMC正常培养液、ox-LDL诱导血管内皮细胞（VEC）损伤的条件培养基、青藤碱加ox-LDL诱导VEC损伤的条件培养基等分别作用于VSMC,采用β-放射活性法等测定MAPK及PKC活性,荧光光度法检测VSMC[Ca^2＋]i。结果：VEC损伤条件培养基作用于VSMC后,与正常培养VSMC相比,细胞MAPK、PKC活性明显增加（P〈0．01）,细胞[Ca^2＋]i增加;青藤碱作用于VEC损伤条件培养基培养的VSMC后,与模型组相比,MAPK及PKC活性明显减少（P〈0．01）、细胞[Ca^2＋]i降低。结论：青藤碱抑制VSMC增殖的作用可能与拮抗MAPK、PKC活性和细胞[Ca^2＋]i的增加有关。     

激光扫描共聚焦显微镜观察胰蛋白酶对肺上皮细胞游离钙离子的影响

目的：研究PAR-2激动剂SLIGKV和tc-LIGRLO、胰蛋白酶及其抑制剂对H292肺上皮细胞[Ca^2＋]i的影响.方法：应用Fluo-3/AM 荧光标记技术和激光扫描共聚焦显微镜（LSCM） 检测不同因素处理的H292肺上皮细胞[Ca^2＋]i.结果：胰蛋白酶、SLIGKV、tc-LIGRLO均能引发H292细胞[Ca^2＋]i的增加,平均荧光强度分别比加入药物前增加267%,60%和37%.胰蛋白酶抑制剂大豆胰蛋白酶抑制剂（SBTI）和α1-抗胰蛋白酶（α1-AT）可以抑制胰蛋白酶诱导的细胞[Ca^2＋]i的增加.结论：PAR-2可以介导H292肺上皮细胞[Ca^2＋]i的释放增加,胰蛋白酶抑制剂可以抑制胰蛋白酶诱导的细胞[Ca^2＋]i的增加.     

mitoKATP通道参与心肌缺血预处理保护作用的机制

目的：探讨血管紧张素转换酶抑制剂（ACEI）和阈下缺血预处理联合预处理诱导的心肌保护作用中mi-toKatp通道激动后的作用机制：方法：采用离体大鼠心脏Langendorff灌流模型,观察心脏电脱耦联发生时间、细胞膜Na^＋／K^＋-ATPase和Ca^2＋/Mg^2＋-ATPase活性的改变：结果：单独使用卡托普利、或给予大鼠心脏2min缺血／10min复灌作为阈下缺血预处理,均不能改善长时间缺血／复灌引起的心脏收缩功能下降？而卡托普利和阂下缺血预处理联合使用可增高心脏收缩功能。mitoKatp通道特异性阻断剂5-HD可取消这一联合预处理的作用一联合预处理可引起缺血后电脱耦联发生时间延长,缺血心肌细胞膜Na^＋／K^＋-ATPase和Ca^2＋/Mg^2＋-ATPase活性增高;5-HD可取消此作用结论：mitoKatp通道参与了联合预处理延迟缺血引起的细胞间脱耦联和促进细胞膜离子通道稳定性维持的作用。     

吗啡对培养海马神经元钙离子作用的机制研究

目的：研究吗啡对海马神经元[Ca^2 ]i影响的机制,为探索吗啡成瘾的神经生物学机制与可能的治疗途径。方法：荧光探针Fluo-4标记细胞内游离钙后,用激光共聚焦显微镜检测吗啡对大鼠原代培养海马神经元[Ca^2 ]i的影响。结果：吗啡急性刺激引起海马神经元[Ca^2 ]i升高,CTOP不能阻断吗啡引起的细胞内[Ca^2 ]i增加,而naltrindole能阻断吗啡引起的细胞内[Ca^2 ]i反应;Thapsigargin预处理阻断吗啡诱导的细胞内[Ca^2 ]i增加,Verapamil预处理不能完全抑制吗啡引起的细胞内[Ca^2 ]i增加;吗啡长时程作用后,海马神经元[Ca^2 ]i升高,加入纳络酮急性戒断后,不能阻断吗啡引起的细胞内[Ca^2 ]i升高,反而引起[Ca^2 ]i异常升高。结论：吗啡急性刺激引起的海马神经元内游离钙增加主要来源于δ2阿片受体介导的IP3敏感的钙库释放。     

Vascular endothelial growth factor increases the intracellular magnesium

Vascular endothelial growth factor (VEGF) is one of the key players in the process of angiogenesis. However, its underlying mechanism remains unclear. Mg2+ is the most abundant intracellular divalent cation in the body and plays critical roles in many cell functions. We investigated the effect of VEGF on intracellular Mg2+ in human umbilical vein endothelial cells (HUVECs). VEGF-A165 increased the intracellular Mg2+ concentration ([Mg2+]i) in a dose-dependent manner, with or without extracellular Mg2+, and the increase of [Mg2+]i was blocked by pretreatment with SU1498, tyrosine kinase inhibitors (tyrphostin A-23 and genistein), phosphatidylinositol 3-kinase (PI3K) inhibitors (wortmannin and LY294002) or phospholipase Cgamma (PLCgamma) inhibitor (U73122). In contrast, mitogen-activated protein kinase inhibitors (SB202190 and PD98059) had no effect on the VEGF-induced [Mg2+]i increase. These results suggest that VEGF-A165 increases the [Mg2+]i from the intracellular Mg2+ stores through the tyrosine kinase/PI3K/PLCgamma-dependent signaling pathways.     

Basic fibroblast growth factor increases intracellular magnesium concentration through the specific signaling pathways

Basic fibroblast growth factor (bFGF) plays an important role in angiogenesis. However, the underlying mechanisms are not clear. Mg²⁺ is the most abundant intracellular divalent cation in the body and plays critical roles in many cell functions. We investigated the effect of bFGF on the intracellular Mg²⁺ concentration ([Mg²⁺]_i) in human umbilical vein endothelial cells (HUVECs). bFGF increased [Mg²⁺]_i in a dose-dependent manner, independent of extracellular Mg²⁺. This bFGF-induced [Mg²⁺]_i increase was blocked by tyrosine kinase inhibitors (tyrphostin A-23 and genistein), phosphatidylinositol 3-kinase (PI3K) inhibitors (wortmannin and LY294002) and a phospholipase Cγ (PLCγ) inhibitor (U73122). In contrast, mitogen-activated protein kinase inhibitors (SB202190 and PD98059) did not affect the bFGF-induced [Mg²⁺]_i increase. These results suggest that bFGF increases the [Mg²⁺]_i from the intracellular Mg²⁺ stores through the tyrosine kinase/PI3K/PLCγ-dependent signaling pathways.     

Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells

Vascular endothelial growth factor (VEGF)-D binds to VEGF receptors (VEGFR) VEGFR2/KDR and VEGFR3/Flt4, but the signaling mechanisms mediating its biological activities in endothelial cells are poorly understood. Here we investigated the mechanism of action of VEGF-D, and we compared the signaling pathways and biological responses induced by VEGF-D and VEGF-A in endothelial cells. VEGF-D induced KDR and phospholipase C-gamma tyrosine phosphorylation more slowly and less effectively than VEGF-A at early times but had a more sustained effect and was as effective as VEGF-A after 60 min. VEGF-D activated extracellular signal-regulated protein kinases 1 and 2 with similar efficacy but slower kinetics compared with VEGF-A, and this effect was blocked by inhibitors of protein kinase C and mitogen-activated protein kinase kinase. In contrast to VEGF-A, VEGF-D weakly stimulated prostacyclin production and gene expression, had little effect on cell proliferation, and stimulated a smaller and more transient increase in intracellular [Ca(2+)]. VEGF-D induced strong but more transient phosphatidylinositol 3-kinase (PI3K)-mediated Akt activation and increased PI3K-dependent endothelial nitric-oxide synthase phosphorylation and cell survival more weakly. VEGF-D stimulated chemotaxis via a PI3K/Akt- and endothelial nitric-oxide synthase-dependent pathway, enhanced protein kinase C- and PI3K-dependent endothelial tubulogenesis, and stimulated angiogenesis in a mouse sponge implant model less effectively than VEGF-A. VEGF-D-induced signaling and biological effects were blocked by the KDR inhibitor SU5614. The finding that differential KDR activation by VEGF-A and VEGF-D has distinct consequences for endothelial signaling and function has important implications for understanding how multiple ligands for the same VEGF receptors can generate ligand-specific biological responses.     

RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3K/Akt pathway

Vascular endothelial growth factor (VEGF) is vital to physiological as well as pathological angiogenesis, and regulates a variety of cellular functions, largely by activating its 2 receptors, fms-like tyrosine kinase (Flt1) and kinase domain receptor (KDR). KDR plays a critical role in the proliferation of endothelial cells by controlling VEGF-induced phospholipase Cγ-protein kinase C (PLCγ-PKC) signaling. The function of Flt1, however, remains to be clarified. Recent evidence has indicated that Flt1 regulates the VEGF-triggered migration of endothelial cells and macrophages. Here, we show that RACK1, a ubiquitously expressed scaffolding protein, functions as an important regulator of this process. We found that RACK1 (receptor for activated protein kinase C 1) binds to Flt1 in vitro. When the endogenous expression of RACK1 was attenuated by RNA interference, the VEGF-driven migration was remarkably suppressed whereas the proliferation was unaffected in a stable Flt1-expressing cell line, AG1-G1-Flt1. Further, we demonstrated that the VEGF/Flt-mediated migration of AG1-G1-Flt1 cells occurred mainly via the activation of the PI3 kinase (PI3K)/Akt and Rac1 pathways, and that RACK1 plays a crucial regulatory role in promoting PI3K/Akt-Rac1 activation.     

糖皮质激素快速抑制气道平滑肌游离钙升高与磷脂酶C活性的关系

目的:本实验通过对平滑肌细胞行GCs快速预处理,拟证实糖皮质激素对平滑肌细胞内[Ca2+]i浓度升高有快速抑制作用,并初步探讨该现象的可能分子机制。方法:原代培养的大鼠平滑肌细胞,应用Fura-2/AM显微荧光检测技术,检测肌细胞内[Ca2+]i在受到激动剂刺激后的浓度变化;比较不同浓度地塞米松预处理后10min与对照组之间游离钙上升情况的区别。用Western blot方法,分析气道平滑肌细胞内抑制型磷脂酶C(phospho-PLCβ-ser1105)含量的变化。设立RU486及CHX对照组,排除基因组作用在该反应中的影响。结果:GCs温浴10min,能够明显降低乙酰胆碱引起的ASMCs细胞内[Ca2+]i峰值。并能够明显上调ASMCs内抑制型PLC含量。这些反应不受RU486和CHX影响。结论:GCs能够通过非基因组作用快速抑制刺激物引起的气道平滑肌的收缩反应,这一效应的实现可能是通过抑制PLC分子活性,使其下游的[Ca2+]i浓度降低实现的。     

Ca~(2+)信号在肿瘤坏死因子-α诱导心肌肥大PI3-K信号途径中的作用

目的:研究Ca2+信号在肿瘤坏死因子-α(TNF-α)诱导心肌细胞肥大PI3-K信号途径中的作用。方法:Lowry法测心肌细胞蛋白含量;计算机图像分析系统测心肌细胞体积;[3H]-亮氨酸掺入法测心肌细胞蛋白合成;Till阳离子测定系统观察胞内[Ca2+]i瞬变。结果:①TNF-α(100μg/L)明显诱导心肌细胞蛋白含量、蛋白合成及体积的增加,PI3-K特异性抑制剂LY294002(50μmol/L)明显抑制TNF-α诱导的心肌肥大,但对正常心肌细胞生长无影响。L型Ca2+通道阻断剂verapamil(1μmol/L)对TNF-α诱导的心肌肥大无明显影响。②TNF-α引起心肌细胞内钙离子浓度([Ca2+]i)瞬间变化幅度增高,LY294002明显降低TNF-α诱导的上述改变,L型Ca2+通道阻断剂verapamil(1μmol/L)对TNF-α引起的变化无明显影响。结论:PI3-K可能通过引起心肌细胞[Ca2+]i升高参与TNF-α诱导的心肌细胞肥大,但与L型Ca2+通道无关。     

Sphingosine 1-phosphate stimulates tyrosine phosphorylation of focal adhesion kinase and chemotactic motility of endothelial cells via the G(i) protein-linked phospholipase C pathway

We have previously shown that sphingosine 1-phosphate (S1P) stimulates motility of human umbilical vein endothelial cells (HUVECs) (O.-H. Lee et al., Biochem. Biophys. Res. Commun. 264, 743-750, 1999). To investigate the molecular mechanisms by which S1P stimulates HUVEC motility, we examined tyrosine phosphorylation of p125 focal adhesion kinase (p125(FAK)) which is important for cell migration. S1P induces a rapid increase in tyrosine phosphorylation of p125(FAK). Compared with other structurally related lipid metabolites such as sphingosine, C2-ceramide, and lysophosphatidic acid, S1P uniquely stimulated p125(FAK) tyrosine phosphorylation and migration of HUVECs. The effect of S1P on p125(FAK) tyrosine phosphorylation was markedly reduced by treatment with pertussis toxin or U73122, a phospholipase C (PLC) inhibitor. As a downstream signal of PLC, p125(FAK) tyrosine phosphorylation in response to S1P was totally blocked by depletion of the intracellular calcium pool. However, protein kinase C (PKC) inhibitor had no effect on the response to S1P. Finally, chemotaxis assays revealed that inhibition of PLC but not PKC significantly abrogated S1P-stimulated HUVEC migration. These results suggest that the G(i)-coupled receptor-mediated PLC-Ca(2+) signaling pathway may be importantly involved in S1P-stimulated focal adhesion formation and migration of endothelial cells.     

Oxytocin stimulates in vitro angiogenesis via a Pyk-2/Src-dependent mechanism

We previously reported that the hypothalamic hormone oxytocin (OT), best known for its uterotonic activity, also stimulates migration and invasion in human umbilical vein endothelial cells (HUVECs), thus suggesting a possible role for the peptide in the regulation of angiogenesis. We identified the Gq coupling of OT receptors (OTRs) and phospholipase C (PLC) as the main effectors of OT's action in HUVECs. Moreover, the pro-migratory effect of OT required the OTR-induced activation of the phosphatidylinositol-3-kinase (PI-3-K)/AKT/endothelial nitric oxide synthase (eNOS) pathway. To better characterize the proposed pro-angiogenic effect of OT in HUVECs, we have now utilized a three-dimensional (3-D) in vitro angiogenesis assay, and demonstrated that OT stimulates the outgrowth of capillary-like structures from HUVEC spheroids to an extent comparable to that of vascular endothelial growth factor (VEGF). This OT effect was abolished by inhibitors of PLC, PI-3-K and Src kinase. It was also found that OT phosphorylates proline-rich tyrosine kinase-2 (Pyk-2) and Src kinase in a PLC- and calcium-dependent manner. Furthermore, knockdown of Pyk-2 expression by RNA interference markedly impaired Src phosphorylation, migration and endothelial cell sprouting induced by OT. In conclusion, by using a pharmacological and genetic approach, the OT pro-angiogenic action and the cascade of intracellular signals responsible for it were defined by showing for the first time that OT, by interacting with its Gq-coupled receptor, induces HUVEC capillary outgrowth via Pyk-2 phosphorylation, which activates Src which in turn activates the PI-3-K/AKT pathway.     

Inhibitors of the tyrosine kinase signaling cascade attenuated thrombin-induced guinea pig airway smooth muscle cell proliferation

Airway remodeling is one of the major hallmarks of asthma. The present study examined the effects of tyrosine kinase inhibitors on thrombin-induced guinea pig ASM cell proliferation, in comparison with inhibitors of mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K). The ASM cells expressed smooth muscle alpha-actin and myosin, and responded to thrombin by increasing cytosolic Ca(+2). Thrombin (1-10 U/ml) induced [(3)H]thymidine incorporation into ASM cells. Tyrphostin 47, a broad-spectrum tyrosine kinase inhibitor, PP2, a Src-specific inhibitor, and piceatannol, a Syk-selective inhibitor, significantly attenuated thrombin-induced [(3)H]thymidine incorporation. In addition, the tyrosine kinase inhibitors significantly reduced thrombin-induced cyclin D(1) expression in ASM cells. PD098059 and U0126, two MAPK kinase inhibitors, and LY294002, a PI3K inhibitor, significantly blocked thrombin-induced [(3)H]thymidine incorporation and cyclin D(1) expression in ASM cells. Our data show that inhibitors of Src and, probably Syk, can modulate thrombin-induced ASM cell proliferation, which may have therapeutic potential for asthma.     

Requirement of protein kinase D tyrosine phosphorylation for VEGF-A165-induced angiogenesis through its interaction and regulation of phospholipase Cgamma phosphorylation

Vascular endothelial cell growth factor-A(165) (VEGF-A(165)) is critical for angiogenesis. Although protein kinase C-mediated protein kinase D(PKD)activation was implicated in the response, the detailed mechanism remains unclear. In this study, we found that VEGF-A(165)-stimulated tyrosine phosphorylation of PKD and the dominant negative mutant of PKD, PKD(Y463F), inhibited VEGF-A(165)-induced human umbilical vein endothelial cell (HUVEC) proliferation. In addition, PKD(S738A/S742A) overexpression inhibited VEGF-induced HUVEC migration. Furthermore, knockdown of PKD by its specific small interfering RNA inhibited VEGF-induced HUVEC proliferation and migration. Moreover transfection of PKD(Y463F), PKD(S738A/S742A), or PKD-small interfering RNA blocked VEGF-induced angiogenesis in vivo. Our signaling experiments show that KDR not Flt-1 mediated PKD tyrosine phosphorylation and KDR tyrosine residues 951 and 1059 were required for VEGF-A(165)-stimulated PKD serine and tyrosine phosphorylation, respectively. Whereas G protein Gbetagamma subunits were required for both PKD serine phosphorylation and tyrosine phosphorylation, intracellular Ca(2+) mobilization was required for VEGF-A(165)-stimulated PKD tyrosine phosphorylation and phospholipase C (PLC) activity was required for PKD serine phosphorylation. Surprisingly, the PLC inhibitor did not inhibit PKD tyrosine phosphorylation. Instead, PKD tyrosine 463 was required for VEGF-A(165)-stimulated PLCgamma tyrosine phosphorylation. Moreover, PKD interacted with PLCgamma even in unstimulated cells, and PKD tyrosine 463 phosphorylation was not required for this interaction. Together, we demonstrate that PKD interacts with PLCgamma and becomes tyrosine phosphorylated upon VEGF stimulation, leading to PLCgamma activation and angiogenic response of VEGF-A(165).